Profiling the Prognosis of Gastric Cancer Patients: Is It Worth Correlating the Survival with the Clinical/Pathological and Molecular Features of Gastric Cancers?

Table 1

Clinical and pathological features of patients who have undergone IHC evaluation for HER2 over-expression in gastric adenocarcinoma from 2003 to 2011.

	n	%
Sex
F	19	24.7
M	58	75.3
Age (years)
Mean		62.8
Median; SD		64.0; 10.2
Range		31–80
Localization
Cardias	16	20.8
Fundus	19	24.7
Antrum	33	42.9
Angulus	4	5.2
Anastomosis	1	1.3
Linitis	4	5.2
HER2 IHC score
HER2 0	45	62.5
HER2 1+	13	18.1
HER2 2+	6	8.3
HER2 3+	8	11.1
Stage
I	18	24.3
II	14	18.9
III	21	28.4
IV	21	28.4
Follow-up (months)
Mean		49.4
Median; SD		59.0; 26.7
Range		3–83